Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
By Dr. Matthew Watson
PRINCETON, N.J., April 28, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced preliminary expectations for first quarter 2023 Twirla® demand, net revenue and operating expenses.
Continue reading here:
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023
By Dr. Matthew Watson
PALO ALTO, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that Henry Ji, Ph.D., Executive Chairman of Scilex, and Jaisim Shah, Chief Executive Officer and President of Scilex will participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq:
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
By Dr. Matthew Watson
NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, May 9, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and Interim CEO; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commerical Officer and Vignesh Rajah, Chief Medical Officer.
Link:
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
Publication of a transparency notification received from Alychlo NV
By Dr. Matthew Watson
Liege, Belgium, 28 April 2023 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from Alychlo NV, with registered offices at Lembergsesteenweg 19. 9820 Merelbeke, on 25, April 2023.
Follow this link:
Publication of a transparency notification received from Alychlo NV
Total number of shares and voting rights in Zealand Pharma at April 28, 2023
By Dr. Matthew Watson
Company announcement – No. 18 / 2023
See the original post:
Total number of shares and voting rights in Zealand Pharma at April 28, 2023
ObsEva Annual Report 2022
By Dr. Matthew Watson
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
See the rest here:
ObsEva Annual Report 2022
Plus Therapeutics Announces Reverse Stock Split
By Dr. Matthew Watson
AUSTIN, Texas, April 28, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-15. The reverse stock split will become effective at 12:01 a.m. Eastern Time on May 1, 2023, and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis on May 1, 2023 under the Company’s existing trading symbol, “PSTV.” At such time, the Company’s common stock will also commence trading with a new CUSIP number, 72941H509.
Here is the original post:
Plus Therapeutics Announces Reverse Stock Split
AB Science reports its revenues for the year 2022 and provides an update on its activities
By Dr. Matthew Watson
PRESS RELEASE
See the original post:
AB Science reports its revenues for the year 2022 and provides an update on its activities
Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023
By Dr. Matthew Watson
THE WOODLANDS, Texas, April 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2023 financial results on Tuesday, May 2, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.
Continue reading here:
Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023
Protect Pharmaceutical Corp.‘s (PRTT) President Ali Yildiz Provides its Shareholders with a Corporate Update
By Dr. Matthew Watson
ISTANBUL, Turkey, April 28, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp.‘s (OTC: PRTT) (“Company”) President Ali Yildiz addresses the Company’s shareholders with a corporate update on expansion and forward-looking progress.
See the rest here:
Protect Pharmaceutical Corp.‘s (PRTT) President Ali Yildiz Provides its Shareholders with a Corporate Update
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
By Dr. Matthew Watson
Regulated Information - Denominator
Continue reading here:
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
By Dr. Matthew Watson
WATERTOWN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a conference call on Thursday, May 4, 2023, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2023 and provide a business update.
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By Dr. Matthew Watson
CAMBRIDGE, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on April 21, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 375,000 restricted stock unit awards (RSUs) to four new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan. The RSUs are being granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule5635(c)(4).
See more here:
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older
By Dr. Matthew Watson
WESTLAKE VILLAGE, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced today that its next-generation topical PDE4 inhibitor therapy for plaque psoriasis, ZORYVE™ (roflumilast) cream 0.3%, has received regulatory approval from Health Canada.
TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update
By Dr. Matthew Watson
Conference call to be held Monday, May 1, 2023, at 8:30 AM ET Conference call to be held Monday, May 1, 2023, at 8:30 AM ET
See the original post here:
TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update
Preliminary Results for the Year Ended 31 December 2022
By Dr. Matthew Watson
To Read More: Preliminary Results for the Year Ended 31 December 2022Neuronetics Announces Expanded TMS Access through United HealthCare
By Dr. Matthew Watson
UHC Medicare Advantage plans in NGS states expand access via NPPs UHC Medicare Advantage plans in NGS states expand access via NPPs
See more here:
Neuronetics Announces Expanded TMS Access through United HealthCare
Predicine to Introduce PredicineALERT™ MRD Assay and Present Two ctDNA Studies in Genitourinary Cancers at AUA 2023 Annual Meeting
By Dr. Matthew Watson
HAYWARD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announced today that it will present two studies and introduce PredicineALERT™ Minimal Residual Disease (MRD) liquid biopsy assay to genitourinary (GU) cancers at the 2023 American Urological Association (AUA) Annual Meeting held in Chicago between April 28 to May 1, 2023.
Read this article:
Predicine to Introduce PredicineALERT™ MRD Assay and Present Two ctDNA Studies in Genitourinary Cancers at AUA 2023 Annual Meeting
Cronos Group Inc. to Hold Virtual 2023 Annual Meeting of Shareholders
By Dr. Matthew Watson
TORONTO, April 28, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2023 Annual Meeting of Shareholders on Thursday, June 22, 2023, at 11:00 a.m. ET.
Read the original post:
Cronos Group Inc. to Hold Virtual 2023 Annual Meeting of Shareholders